share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Guarini Kathryn

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Guarini Kathryn

再生元製藥公司 | 4:持股變動聲明-董事 Guarini Kathryn
美股SEC公告 ·  01/07 05:11

Moomoo AI 已提取核心訊息

On January 2, 2025, Kathryn Guarini, an insider at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition, classified under the transaction code 'A' for grant, award, or other acquisition.Following this transaction, Guarini's direct ownership of Regeneron Common Stock increased to 448 shares. The acquisition was completed on the reported date, with no additional transactions or disposals mentioned in the filing.
On January 2, 2025, Kathryn Guarini, an insider at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition, classified under the transaction code 'A' for grant, award, or other acquisition.Following this transaction, Guarini's direct ownership of Regeneron Common Stock increased to 448 shares. The acquisition was completed on the reported date, with no additional transactions or disposals mentioned in the filing.
2025年1月2日,內線人士凱瑟琳·瓜里尼在再生元製藥公司獲得了166股普通股,每股價格爲0美元。此交易被報告爲直接收購,分類爲交易代碼'A',代表贈予、獎勵或其他收購。在此次交易之後,瓜里尼在再生元普通股的直接持有量增加到448股。收購在報告日期完成,文件中未提及任何額外的交易或處置。
2025年1月2日,內線人士凱瑟琳·瓜里尼在再生元製藥公司獲得了166股普通股,每股價格爲0美元。此交易被報告爲直接收購,分類爲交易代碼'A',代表贈予、獎勵或其他收購。在此次交易之後,瓜里尼在再生元普通股的直接持有量增加到448股。收購在報告日期完成,文件中未提及任何額外的交易或處置。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息